Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

Baicalein enhances immune response in TNBC by inhibiting leptin expression of adipocytes

Liu M., Li C., Qu J., Sun S., Zhao Z., Wang W.

Laboratory Study, published in Cancer Sci (2023) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Cancer Sci (2023)
Reported sample size
—
Source database
Europe PMC
PMID
37489486
PMCID
PMC10551602
DOI
10.1111/cas.15916
Citations
11

Abstract (original English)

Triple-negative breast cancer (TNBC) is a special pathological type of breast cancer (BC) with poor prognosis. Obesity is shown to be involved in TNBC tumor progression. The interaction between obesity and BC has generated great attention in recent years, however, the mechanism is still unclear. Here, we showed that leptin secreted by adipocytes upregulated PD-L1 expression in TNBC through the p-STAT3 signaling pathway and that baicalein inhibited PD-L1 expression in tumor microenvironment by suppressing leptin transcription of adipocytes. Collectively, our findings suggest that leptin may be the key factor participating in obesity-related tumor progression and that baicalein can break through the dilemma to boost the anti-tumor immune response.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Cell Line, TumorAdipocytesHumansObesityFlavanonesLeptinImmunityTumor MicroenvironmentTriple Negative Breast NeoplasmsB7-H1 Antigen

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.